Laminar Pharmaceuticals S.A., empresa biotecnológica española en fase clínica centrada en el desarrollo de nuevas terapias para tratar diversas patologías con altas necesidades médicas, se complace en anunciar el reclutamiento de los primeros 45 pacientes en el estudio clínico de fase II/III en glioblastoma de...
Development of new drugs for this hard-to-treat brain cancer is a slow and incremental process....
The Spanish Bioindustry Association (AseBio), where Laminar Pharma is a member, has published its latest annual report on the state of the biotech sector in Spain, with updated data from 2020. ...
Laminar Pharma has signed an agreement to sponsor the charity Sonrisa Médica, whose mission is to make hospital stays bearable for children, through laughter and magic....
“If someone has done it before, I can do it too – if no one has done it, I can be the first”: for 30 years, this compass has guided the prolific scientific career of Dr. Pablo Escribá, founder and CEO of Laminar Pharma....
Alicante Science Park Foundation (PCA) and Laminar Pharmaceuticals have signed today the contract by which the biotechnology company is linked to the PCA....
In 2020, biologist Gema Malet Engra joined our company after a successful 15-year career in fundamental and applied research in Oncology at several international research centers. ...
On the last day of February — a month known for having a ‘rare’ number of days — we commemorate Rare Disease Day to celebrate their strength, to share their stories and to champion research that will improve these patients’ lives....
On January 2021, the researchers whose projects have received funding from the CAIB 2020 call of the Balearic Government for the promotion of hiring of research staff were announced: Ramón Román Roldán has been selected, and he will join the Research Unit of Laminar Pharma....
Society needs social change agents who are committed to creating a better world than the one they found. ...